Eisai Establishes Pharma Sales Subsidiary in Moscow Ahead of Pla

Eisai Establishes Pharma Sales Subsidiary in Moscow Ahead of Planned Direct
Sales Launch in Russia 
Tokyo, Apr 5, 2013 - (JCN Newswire) -  Eisai Co., Ltd. announced today that it
has established a new pharmaceutical sales subsidiary in Moscow, Russia, which
will be named Limited Liability Company Eisai ("Eisai Russia"). Eisai
Russia will function as a direct subsidiary of Eisai's U.K. pharmaceutical
operation, Eisai Europe Ltd. 
The Russian pharmaceutical market constitutes the 11th largest in the world
and is expected to achieve double-digit growth going forward. Eisai established
a representative office in Moscow in October 2007 and has since been working to
complete product registration procedures, with marketing approval received in
Russia for anticancer agent Halaven(R) (eribulin mesylate) and antiepileptic
agents Zonegran(R) (zonisamide) and Exalief(R) (eslicarbazepine acetate, brand
name in the EU: Zebinix(R)) in fiscal 2012. The establishment of new sales
subsidiary Eisai Russia is part of Eisai's preparations to expand direct
sales operations into the Russian healthcare market. Eisai Russia plans to
launch Halaven in the first quarter of fiscal 2013, followed by respective
launches of Zonegran and Exalief. In addition, Eisai has also filed for
regulatory approval in Russia for AMPA receptor antagonist Fycompa(R)
(perampanel). 
As part of Eisai's globalization strategy defined in its midterm
strategic plan, "HAYABUSA," the company aims to expand its operations
into all of the world's top 20 largest pharmaceutical markets to
effectively make contributions to more than 500 million patients worldwide.
Through the establishment of Eisai Russia, Eisai expects to deliver its
innovative pharmaceutical products to patients in Russia as well as to increase
the benefits provided to patients and their families across the region. 
Outline of New Subsidiary 
1) Company Name: Limited Liability Company Eisai
2) Location: Moscow, Russia
3) General Manager: Igor Galaburda
4) Scope of Business: Marketing and promotion of pharmaceutical products
5) Charter Capital: 163 million Russian rubles (4 million euro)
6) Major Shareholder: Eisai Europe Limited
7) Date of Establishment: April 1, 2013 (local time) 
About Eisai's Globalization Strategy as Outlined Under Its Midterm
Strategic Plan, "HAYABUSA" 
Eisai has set the goal of entering the world's top 20 largest
pharmaceutical markets as part of the company's globalization strategy
outlined in its midterm strategic plan, "HAYABUSA." Of the eight
countries (Russia, Canada, Brazil, Australia, Turkey, Poland, Mexico, and
Venezuela) that Eisai announced it would enter as part of that strategy when
the "HAYABUSA" plan was launched in March 2011, the company has
already established pharmaceutical sales subsidiaries in countries other than
Russia; namely, Australia (January 2006), Canada (April 2010), Brazil (April
2011), and Mexico (August 2011). Eisai seeks to address the significant unmet
medical needs that exist in both mature and emerging markets by improving
access to medicines through its provision of comprehensive disease solutions,
engagement in public-private partnerships and other initiatives, and the
implementation of its affordable pricing policy, among other activities. 
Furthermore, the company aims to dramatically expand the total number of
patients it serves from the just over 200 million it recorded for the period
from fiscal 2006 through fiscal 2010, to its current target of more than 500
million patients for the five-year period between fiscal 2011 and fiscal 2015.
In doing so, Eisai believes it will be able to better contribute to increasing
the benefits provided to as many patients and their families as possible
worldwide. 
About Eisai 
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care
(hhc) company that discovers, develops and markets products throughout the
world. Eisai focuses its efforts in three therapeutic areas: integrative
neuroscience, including neurology and psychiatric medicines; integrative
oncology, which encompasses oncotherapy and supportive-care treatments; and
vascular/immunological reaction. Through a global network of research
facilities, manufacturing sites and marketing subsidiaries, Eisai actively
participates in all aspects of the worldwide healthcare system. For more
information about Eisai Co., Ltd., please visit www.eisai.com. 
Contact: 
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120 
Copyright 2013 JCN Newswire. All rights reserved. www.japancorp.net 
Provider ID: 00026559
 
 
Press spacebar to pause and continue. Press esc to stop.